Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • abbvie

    Tag: abbvie

    You Searched For "abbvie"
    AstraZeneca leukemia drug Calquence gets USFDA okay

    AstraZeneca leukemia drug Calquence gets USFDA okay

    Medical Dialogues Bureau24 Nov 2019 4:30 AM GMT
    New Delhi: AstraZeneca said late on Thursday that the U.S. Food and Drug Administration (FDA) had given its go-ahead for the company's Calquence drug...
    BeiGene gets USFDA approval for lymphoma drug Brukinsa

    BeiGene gets USFDA approval for lymphoma drug Brukinsa

    Medical Dialogues Bureau17 Nov 2019 3:50 AM GMT
    BeiGene tested the treatment, Brukinsa, in 118 patients with mantle cell lymphoma enrolled in two studies. About three-quarters were Asian, 21%...
    AbbVie says multiple parties vying for assets related to Allergan deal approval

    AbbVie says multiple parties vying for assets related to Allergan deal approval

    Medical Dialogues Bureau4 Nov 2019 3:30 AM GMT
    AbbVie Inc said it had notified the U.S. antitrust watchdog of its intention to divest its experimental inflammatory bowel disease therapy,...
    Allergan shareholders okays USD 63 billion AbbVie acquisition

    Allergan shareholders okays USD 63 billion AbbVie acquisition

    Medical Dialogues Bureau15 Oct 2019 4:00 AM GMT
    Under the terms of the agreement announced on June 25, 2019, AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity...
    AbbVie wins USFDA nod for new rheumatoid arthritis drug priced at Rs 41 lakh per year

    AbbVie wins USFDA nod for new rheumatoid arthritis drug priced at Rs 41 lakh per year

    Medical Dialogues Bureau18 Aug 2019 4:06 AM GMT
    A four-week supply of Humira, the world's best-selling medicine, has a list price of about $5,174, amounting to more than $60,000 for a year.U.S:...
    Abbvie finalizes deal to buy Botox maker Allergan for $63 billion

    Abbvie finalizes deal to buy Botox maker Allergan for $63 billion

    Medical Dialogues Bureau26 Jun 2019 4:30 AM GMT
    A note from Moody's affirmed Abbvie's debt rating, saying a plan to reduce debt through existing blockbusters like AbbVie's Humira and Imbruvica and...
    AbbVie wins USFDA nod for Mavyret to treat HCV genotypes in pediatric patients

    AbbVie wins USFDA nod for Mavyret to treat HCV genotypes in pediatric patients

    Farhat Nasim3 May 2019 3:40 AM GMT
    New Delhi: AbbVie Inc. recently won the U.S. Food and Drug Administration (USFDA) approval for Mavyret (glecaprevir and pibrentasvir) tablets to treat...
    USFDA puts partial hold on Abbvie Venclexta clinical trials after deaths

    USFDA puts partial hold on Abbvie Venclexta clinical trials after deaths

    Farhat Nasim21 March 2019 4:15 AM GMT
    The clinical hold does not impact any of the approved indications for Venclexta, such as chronic lymphocytic leukaemia (CLL) or acute myeloid...
    Abbvie to record $4 billion impairment charges on Stemcentrx assets

    Abbvie to record $4 billion impairment charges on Stemcentrx assets

    Medical Dialogues Bureau6 Jan 2019 3:30 AM GMT
    The drugmaker acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016, as it aimed to enter the broad and lucrative arena of solid...
    Lupin and AbbVie announces partnership to develop, commercialize Novel Oncology Drug

    Lupin and AbbVie announces partnership to develop, commercialize Novel Oncology Drug

    Medical Dialogues Bureau24 Dec 2018 4:00 AM GMT
    Mumbai: Pharma major Lupin and global biopharmaceutical company AbbVie Inc., announced that AbbVie has licensed Lupin's MALT1 (Mucosa-Associated...
    AbbVie wins US trial in lawsuit over AndroGel

    AbbVie wins US trial in lawsuit over AndroGel's risks

    Medical Dialogues Bureau29 Jan 2018 4:00 AM GMT
    A federal jury in Chicago found AbbVie Inc not liable in a lawsuit by an Arizona man who claimed he had suffered a pulmonary embolism due to using the...
    Roche, AbbVie leukemia drug superior to older medicine in study

    Roche, AbbVie leukemia drug superior to older medicine in study

    Ruby Khatun Khatun24 Nov 2017 4:15 AM GMT
    Patients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without...
    Next

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier

    This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

    Search only trustworthy HONcode health websites:

    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

    © 2020 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    X